Our Specialized Medical and Scientific Writing Services to Support your Regulatory and Clinical Development Needs
Medical Writing plays a pivotal role to define the path of medical research and clinical development. The art of synthesizing information from past research outcomes and developing new scientific knowledge for a medicinal product requires a talented multi-disciplinary team with access to a wide-range of scientific literature databases.
At Techsol, our expert team of Medical writers have an extensive research background, scientific knowledge, and ample experience in clinical development to generate clear and concise manuscripts, publications, and clinical trial protocols across various therapeutic areas. We have the expertise to analyze, understand and apply critical thinking to author valuable scientific reports, protocols, manuscripts, and publications in accordance with applicable regulatory guidelines.
Our team has been helping several pharma companies for regulatory writing, performing the quality review, conducting a technical review of dossiers, and identifying gaps in already compiled documents. Our Clinical and Non- clinical writing services are delivered as per the regulatory compliance requirements mandated by regional Health Authorities (HAs) of North America, the EU, Australia, and New Zealand.
Our team has proven expertise to draft the below deliverables with the highest quality across therapeutic areas for clinical development.
- Clinical Study Concept & Protocol Synopsis
- Clinical Study Protocol Development (Phase I to IV)
- Pharmacokinetic Study Design
- Clamp Study
- Pharmacokinetics & Pharmacodynamics (PK/PD)
- Adaptive Clinical Trial Design
- Post-marketing Surveillance (PMS) Study Design
- Real-World Evidence (RWE) Study Design
Study Essential Documents Preparation
-
-
- Case Report Form (CRF)
- Informed Consent Form (ICF)
- Patient Information Sheet
- Patient Diaries
- Survey Questionnaires
-
- Investigator Brochure Preparation
- Study Reference Manuals
- Clinical Study / Trial Reports (CSRs / CTRs)
- CSR Synopsis for public disclosure
- Clinical and Non-clinical sections of the CTD
- Clinical Overview Summaries for EU and US
- Patient Safety Narratives
- Scientific Literature Review Reports
- Clinical Investigation Plan
- CER Writing (Clinical Evaluation Report)
- PER Writing (Performance Evaluation Report)
- PMCF Plan (Post Marketing Clinical Follow up)
- PMCF Report
- Manuscript Writing and Publications Support
- Biocompatibility Reports Writing
- Toxicology Reports Writing
- CMC / Analyte Report Writing
- Non-Clinical Overviews Reports
- Non-Clinical Summaries Reports
- CTD Module IV Non-Clinical Study Reports
- PDE (Permitted Daily Exposure) Reports
Overview of Permitted Daily Exposure (PDE)
When two or more medicinal products are manufactured in a common facility, the residual ingredients, and derivatives of one product could cross-contaminate the production of another product. These cross-contaminants may not therapeutically benefit the patient or target animal but there is a greater chance that it could pose a health risk. Hence, API manufacturers are expected to determine the threshold value (e.g. permitted daily exposure (PDE) or threshold of toxicological concern (TTC) that can be referenced to identify the extent of health risk due to cross-contamination and implement the corresponding risk-mitigation actions. The PDE represents a substance-specific dose that is unlikely to cause an adverse effect if an individual is exposed at or below this dose every day for a lifetime.
How We Can Help
Our team of certified Toxicologists and Medical Professionals have extensive experience in calculating the PDE values for different types of medicinal products.
We specialize in authoring comprehensive PDE reports through the structured scientific evaluation of all available pharmacological and toxicological data including both non-clinical and clinical data as per the regulatory requirements outlined in EMA/CHMP/CVMP/SWP/169430/2012.
Our Capabilities
We have successfully engaged with several API manufacturers to deliver PDE reports with the following capabilities:
- Expertise in PDE reports writing in compliance with EMA and FDA Q3D(R1) Elemental Impurities Guidance.
- Sound scientific knowledge and experience in identification of critical effects, point of departures (PODs), the no-observed-adverse-effect level (NOAEL) or no observed effect level (NOEL) and lowest-observed-adverse-effect-level (LOAEL) from most appropriate non-clinical / clinical studies.
- Multidisciplinary team of toxicologists and non-clinical experts with hands-on experience of in vitro and in vivo toxicology studies involved in the drafting of the reports.
- Reports reviewed and approved by American board certified (DABT) and European Registered Toxicologists (ERT) with extensive experience in regulatory toxicology.
- Robust quality control checks right from document compilation to sign-off stages
- Quick turnaround time for PDE and OEL reports as per client’s timelines
- Flexibility to adapt to client-specific templates and requirements including priority deliveries of the reports in almost half the time compared to the standard time in the industry for the same task.
- Timely identification of accurate POD to ensure precise PDE value.
Medical and Scientific communications play an important role to bridge the gap between pharma companies and their customers. It is highly important that unbiased and accurate medical information is shared to HCPs, Care Givers and Patients at the right time for a given medicinal product or medical device.
With our qualified team of skilled and experienced medical writing professionals, we can deliver the following types of medical and scientific content tailored to your business needs.
- Abstracts
- Manuscripts
- Marketing Content Development
- Medical Information Content Authoring
- Therapeutic Content Presentations
- Conference Materials (Abstracts, Poster presentations and slides)
- Journal and conference submissions
- Medical marketing reviews and reports
- Periodic safety update reports (PSURs)
- Periodic benefit-risk evaluation reports (PBRERs)
- US Food and Drug Administration periodic line listings
- Risk management plans (RMPs)
- Development safety update reports (DSURs) / Annual Safety Reports (ASR)
- Periodic Adverse Drug Experience Reports (PADER / PAER)
- Local safety summaries (LSSs)
- Signal analyses
- Clinical overviews
Latest News & Updates
How to Proactively Prevent Clinical Trial Protocol Deviations and Protocol Violations
Understanding the Importance of a Clinical Trial Protocol The fundamental objective of a clinical trial protocol is to provide common scientific guidance on how to conduct the clinical study in a regulatory-compliant manner and gather data that will ultimately provide answers on the safety and efficacy of the investigational medicinal product. The Guidelines for Good [...]
Food & Nutraceuticals: How Companies can Prove Health Value with Clinical Trials
What are Food and Nutraceuticals? ‘Nutraceuticals’ is a composite term of ‘nutrition’ and ‘pharmaceutical’. They are a blend of products that possess both nutritional as well as medicinal value. They are designed to improve physical health, boost immunity, and deal with stress and increase longevity. Nutraceutical products play a significant role in maintaining normal physiological [...]
Best Practices for Signal Management in Pharmacovigilance
Pharmacovigilance involves the collection, detection, assessment, and monitoring of data on Adverse Drug Reactions (ADRs) which must be evaluated to derive vital safety information. Signal detection involves monitoring the adverse reaction data for patterns that suggest new safety information. Safety signals can be detected from an extensive range of sources, such as spontaneous reports, clinical [...]